Clinical trial
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
NCT00004212 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00004212 |
|---|---|
| Title | DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas |
| Official title | A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, exatecan mesylate |
| Start date | Sep 1, 1999 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | May 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: